Latest Headlines

  1. Kazia Executes Licensing Agreement With QIMR Berghofer 9/12/2024

    Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that an agreement has been executed with QIMR Berghofer Medical Research Institute, one of Australia's foremost cancer research centres, to obtain an exclusive license to certain intellectual property rights in relation to combination therapies consisting of PI3K inhibitor drugs, and one or more immunotherapy or PARP inhibitor drugs (PI3K combination).

  2. Next-Generation TFF Cassette, Vivaflow® SU, Delivers Intuitive, Effortless, And Sustainable Ultrafiltration To Research Scientists 9/10/2024

    The life science group Sartorius is launching Vivaflow® SU, setting a new standard for laboratory-dedicated tangential flow filtration (TFF). Designed for enhanced ease of use and flexibility, Vivaflow® SU ensures more efficient and sustainable ultrafiltration and diafiltration processes for feed volumes ranging from 100 to 1,000 mL

  3. Researchers Identify New Tools For Anti-Acinetobacter Drug Development And AMR Preparedness 9/10/2024

    University of Liverpool researchers have engineered a library of strains that can be used to develop new antibacterial compounds to help address antimicrobial resistance (AMR) in Acinetobacter baumannii bacteria.

  4. Gilead And Genesis Therapeutics Announce Strategic Collaboration To Discover And Develop Novel Therapies 9/10/2024

    Gilead Sciences, Inc. and Genesis Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.

  5. AISA Pharma Receives FDA Orphan Drug Designation For AISA-021 For Treatment Of Systemic Sclerosis 9/9/2024

    Aisa Pharma, Inc. a private, clinical-stage biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AISA-021(cilnidipine), a fourth-generation calcium channel antagonist.

  6. ARS Pharmaceuticals Submits sNDA To FDA For neffy® 1 mg Dose For Pediatric Patients With Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.) 9/9/2024

    ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today the submission of a supplemental New Drug Application (sNDA) for neffy® 1 mg for the treatment of Type I Allergic Reactions, including anaphylaxis, in children who weigh 15 to 30 kg (33-66 lbs.).

  7. Scientist.com And Evotec Partner To Accelerate Drug Discovery And Development 9/9/2024

    Scientist.com, the leading research platform for the pharmaceutical industry, has announced a new partnership with Evotec SE, a leading drug discovery and development company.

  8. Urate Transporter Structures Reveal The Mechanism Behind Important Drug Target For Gout 9/9/2024

    Scientists at St. Jude Children’s Research Hospital have used cryo-electron microscopy to generate ten structures of URAT1, a protein linked to gout.

  9. Scientists Discover How To Drug Wily Disease-Causing Enzymes 9/9/2024

    UCSF scientists have discovered how to target a large family of molecular switches called GTPases that are involved in myriad diseases, from Parkinson’s to cancer, and have long been thought to be “undruggable.”

  10. Ligand Partner Travere Therapeutics Receives Full FDA Approval For FILSPARI (sparsentan), The Only Non-Immunosuppressive Treatment That Significantly Slows Kidney Function Decline In IgA Nephropathy 9/6/2024

    Ligand Pharmaceuticals Incorporated today announced that its partner Travere Therapeutics, Inc. has received full approval from the U.S. Food and Drug Administration (FDA) for FILSPARI (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression.